All In Biotech

Drug Trial Radar · NCT06718101

A Study to Evaluate the Effectiveness and Safety of Treatments, Either Alone or in Combination, for the Treatment of Moderate to Severe Atopic Dermatitis

A Phase 2 Multicenter Platform Trial of Targeted Immunomodulator Therapies for Moderate to Severe Atopic Dermatitis

Last checked: Nov 20, 2026Latest source record: Aug 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

83

Actual

Start

Dec 19, 2024

Primary completion

May 2027

Study completion May 2027

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Dec 5, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Atopic dermatitis (AD) is a skin condition that may cause a rash and itching due to inflammation of the skin. The purpose of this study is to evaluate the clinical efficacy and safety of single therapies and/or combination therapies for moderate to severe AD through multiple substudies. This study will consist of multiple substudies. Substudy 1 will have a randomized, open-label period 1 followed by a lutikizumab treatment period 2 enrolling 80 participants at a 1 to 1 ratio. In Substudy 1, participants will receive subcutaneous (SC) injections of lutikizumab or matching placebo every other week for 16 weeks followed by an additional 32 weeks of SC injections of lutikizumab every other week for a total of 52 weeks. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at a hospital or clinic and may require frequent medical assessments, blood tests, and biomarker collections.

Conditions

  • Atopic Dermatitis

Interventions

  • LutikizumabDrug

    Subcutaneous (SC) Injection

  • PlaceboDrug

    Subcutaneous (SC) Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16Time frame: At Week 16
  2. Percentage of Participants Who Reported Adverse EventsTime frame: Up to Week 52

Locations

30 sites in 4 countries. Site status is shown where the registry gives one.

  • Peak Dermatology Aesthetics and Wellness Fountain Hills /ID# 272550

    Fountain Hills, Arizona

  • Dermatology Research Associates - Los Angeles /ID# 272945

    Los Angeles, California

  • Integrative Skin Science and Research /ID# 274243

    Sacramento, California

  • Clinical Trials Research Institute /ID# 274234

    Thousand Oaks, California

  • Western States Clinical Res /ID# 271748

    Wheat Ridge, Colorado

  • Skin Care Research Boca Raton /ID# 272544

    Boca Raton, Florida

  • Research Associates of South Florida /ID# 272549

    Miami, Florida

  • Advanced Clinical Research Institute - Tampa /ID# 272558

    Tampa, Florida

  • Encore Medical Research - Weston /ID# 272539

    Weston, Florida

  • Arlington Dermatology /ID# 271735

    Rolling Meadows, Illinois

  • Somnos Clinical Research /ID# 272943

    Lincoln, Nebraska

  • Equity Medical /ID# 272555

    New York, New York

  • Oregon Dermatology and Research Center /ID# 271733

    Portland, Oregon

  • Clinical Partners /ID# 271791

    Johnston, Rhode Island

  • Health Concepts /ID# 271744

    Rapid City, South Dakota

  • Orion Clinical Research /ID# 274236

    Austin, Texas

  • Complete Dermatology - Sugar Land /ID# 274240

    Sugar Land, Texas

  • Dermatology Associates of Tyler /ID# 273684

    Tyler, Texas

  • Center for Clinical Studies - Clear Lake /ID# 271749

    Webster, Texas

  • Medical Corporation Kojinkai Sapporo Dermatology Clinic /ID# 273619

    Sapporo, Hokkaido, Japan

  • Kyoto University Hospital /ID# 275237

    Kyoto, Kyoto, Japan

  • Tachikawa Dermatology Clinic /ID# 273620

    Tachikawa-shi, Tokyo, Japan

  • Korea University Ansan Hospital /ID# 271786

    Ansan-si, Gyeonggido, South Korea

  • Soon Chun Hyang University Hospital Bucheon /ID# 271788

    Bucheon-si, Gyeonggido, South Korea

  • Seoul National University Hospital /ID# 271787

    Seoul, Seoul Teugbyeolsi, South Korea

  • Konkuk University Medical Center /ID# 271789

    Seoul, Seoul Teugbyeolsi, South Korea

  • Hallym University Kangnam Sacred Heart Hospital /ID# 271785

    Seoul, Seoul Teugbyeolsi, South Korea

  • Royal Liverpool University Hospital /ID# 272584

    Liverpool, United Kingdom

  • Royal United Hospital /ID# 274328

    Bath, Bath And North East Somerset, United Kingdom

  • Chapel Allerton Hospital /ID# 274762

    Leeds, West Yorkshire, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.